drugset / Trial / NCT05478603

A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction

NCT05478603

Phase 1 Completed 24 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of this study is to understand the effects of liver functional impairment on the study medicine (PF-07081532). People with liver functional impairment may process the study medicine differently from healthy people. We are seeking participants who: * Are between 18 and 70 years of age; * Have a BMI (body mass index) of 17.5 to 38.0 kg/m2, inclusive, and a total body weight \>50 kg (110 lbs.). Participants will take the study medicine as a tablet once at the study clinic, and then will stay onsite for about 7 days. During this time, the study team will monitor their treatment experience and take some blood samples to test the level of PF-07081532. This will help us understand if certain level of liver functional impairment could affect the study medicine being processed in the body.

Timeline

Start
2022-08-01
Primary completion
2023-04-05
Completion
2023-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject lotiglipron Small molecule 20 mg Oral

Indications

No indication recorded.